PT  - JOURNAL ARTICLE
AU  - Berna, Amalia Z.
AU  - Akaho, Elikplim H.
AU  - Harris, Rebecca M.
AU  - Congdon, Morgan
AU  - Korn, Emilie
AU  - Neher, Samuel
AU  - M’Farrej, Mirna
AU  - Burns, Julianne
AU  - John, Audrey R. Odom
TI  - Reproducible breath metabolite changes in children with SARS-CoV-2 infection
AID  - 10.1101/2020.12.04.20230755
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.12.04.20230755
4099  - http://medrxiv.org/content/early/2021/05/07/2020.12.04.20230755.short
4100  - http://medrxiv.org/content/early/2021/05/07/2020.12.04.20230755.full
AB  - SARS-CoV-2 infection is diagnosed through detection of specific viral nucleic acid or antigens from respiratory samples. These techniques are relatively expensive, slow, and susceptible to false-negative results. A rapid non-invasive method to detect infection would be highly advantageous. Compelling evidence from canine biosensors and studies of adults with COVID-19 suggests that infection reproducibly alters human volatile organic compounds (VOCs) profiles. To determine whether pediatric infection is associated with VOC changes, we enrolled SARS-CoV-2-infected and -uninfected children admitted to a major pediatric academic medical center. Breath samples were collected from children and analyzed through state-of-the-art GCxGC-ToFMS. Isolated features included 84 targeted VOCs. Candidate biomarkers that were correlated with infection status were subsequently validated in a second, independent cohort of children. We thus find that six volatile organic compounds are significantly and reproducibly increased in the breath of SARS-CoV-2-infected children. Three aldehydes (octanal, nonanal, and heptanal) drew special attention, as aldehydes are also elevated in the breath of adults with COVID-19. Together, these biomarkers demonstrate high accuracy for distinguishing pediatric SARS-CoV-2 infection and support the ongoing development of novel breath-based diagnostics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institutes of Health [grant numbers: R61-DH105594, R01-AI103280, R21-AI123808, and R21-AI130584], and AOJ is an Investigator in the Pathogenesis of Infectious Diseases (PATH) of the Burroughs Wellcome Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:the study was approved by the CHOP Human Research Ethics Committee (IRB 20-017503)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript is included in the figures of the manuscript. Supplemental material is also included in the link